To address the major unmet clinical and patient needs in endocrinology by creating products for the lifelong treatment of chronic conditions.
Founded in 2004, Diurnal Group plc is a European, UK-headquartered pecialty pharmaceutical company dedicated to developing products for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism. We are committed to addressing major unmet clinical and patient needs in hormone replacement, initially by developing and marketing products for the rare diseases Congenital Adrenal Hyperplasia (CAH) and Adrenal Insufficiency (AI).
Diurnal is committed to public disclosure and transparency of our clinical study data. Diurnal is committed to transparency in clinical trials and publishes the protocols and results of its clinical trials on the website. Diurnal agrees to share upon request from qualified scientific and medical researchers patient- and study-level clinical study data and protocols from clinical studies in patients for medicines and indications approved by national regulatory authorities..